College of Business Administration, Cal Poly Pomona, Pomona, California, United States of America.
School of Medicine, Wake Forest University, Winston-Salem, North Carolina, United States of America.
PLoS One. 2022 May 24;17(5):e0268828. doi: 10.1371/journal.pone.0268828. eCollection 2022.
Around the world, governments make substantial investments in public sector research and development (R&D) entities and activities to generate major scientific and technical advances that may catalyze long-term economic growth. Institutions ranging from the Chinese Academy of Sciences to the French National Centre for Scientific Research to the Helmholtz Association of German Research Centers conduct basic and applied R&D to create commercially valuable knowledge that supports the innovation goals of their respective government sponsors. Globally, the single largest public sector R&D sponsor is the U.S. federal government. In 2019 alone, the U.S. government allocated over $14.9 billion to federally funded research and development centers (FFRDCs), also known as national labs. However, little is known about how federal agencies' utilization of FFRDCs, their modes of R&D collaboration, and their adoption of non-patent intellectual property (IP) policies (copyright protection and materials transfer agreements) affect agency-level performance in technology transfer. In particular, the lack of standardized metrics for quantitatively evaluating government entities' effectiveness in managing innovation is a critical unresolved issue. We address this issue by conducting exploratory empirical analyses of federal agencies' innovation management activities using both supply-side (filing ratio, transfer rate, and licensing success rate) and demand-side (licensing income and portfolio exclusivity) outcome metrics. We find economically significant effects of external R&D collaborations and non-patent IP policies on the technology transfer performance of 10 major federal executive branch agencies (fiscal years 1999-2016). We discuss the scholarly, managerial, and policy implications for ongoing and future evaluations of technology transfer at federal labs. We offer new insights and guidance on how critical differences in federal agencies' interpretation and implementation of their R&D management practices in pursuit of their respective missions affect their technology transfer performance outcomes. We generalize key findings to address the broader innovation processes of public sector R&D entities worldwide.
在全球范围内,各国政府在公共部门的研究与开发(R&D)实体和活动上投入了大量资金,以取得可能推动长期经济增长的重大科学和技术进步。从中国科学院到法国国家科学研究中心,再到德国亥姆霍兹联合会下属的研究中心,这些机构都在进行基础和应用研究与开发,创造具有商业价值的知识,以支持各自政府资助者的创新目标。在全球范围内,最大的公共部门 R&D 资助者是美国联邦政府。仅在 2019 年,美国政府就向联邦资助的研究和开发中心(FFRDC)拨款超过 149 亿美元,这些中心也被称为国家实验室。然而,人们对联邦机构如何利用 FFRDC、它们的 R&D 合作模式以及采用非专利知识产权(IP)政策(版权保护和材料转让协议)影响机构层面的技术转让绩效知之甚少。特别是,缺乏用于定量评估政府实体在管理创新方面的有效性的标准化指标是一个关键的未解决问题。我们通过使用供应方(备案率、转让率和许可成功率)和需求方(许可收入和投资组合排他性)的结果指标对联邦机构的创新管理活动进行探索性实证分析,解决了这个问题。我们发现,外部 R&D 合作和非专利 IP 政策对 10 个主要联邦行政机构(1999-2016 财年)的技术转让绩效有显著的经济影响。我们讨论了这些发现对联邦实验室正在进行和未来的技术转让评估的学术、管理和政策意义。我们提供了新的见解和指导,说明联邦机构在追求各自使命时对其 R&D 管理实践的解释和实施的关键差异如何影响其技术转让绩效结果。我们将关键发现推广到全球公共部门 R&D 实体的更广泛的创新过程中。